ArticleDrugs in context2026
Efficacy and safety of an Ayurvedic Menohelp syrup in the management of heavy menstrual bleeding (menorrhagia): an open-label clinical study.
Article in Drugs in context, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heavy menstrual bleeding (HMB) is a common gynaecological condition that significantly affects the quality of life and daily functioning amongst women of reproductive age. In Ayurveda, this condition is described under the category of Asrigdara. Menohelp Syrup, an Ashoka ( Methods: This open-label clinical study included 228 non-pregnant women with HMB aged 18-45 years. Participants received Menohelp Syrup at a dose of 15 mL twice daily for 90 days. The primary outcome was menstrual blood loss assessed using the Pictorial Blood Assessment Chart. Secondary outcomes included bleeding duration, cycle regularity, pain-related symptoms, haemoglobin and haematological parameters, endometrial thickness, and quality of life assessed using the Menorrhagia Impact Questionnaire. Results: Treatment with Menohelp Syrup resulted in a substantial reduction in menstrual blood loss, with a 54% decrease in estimated menstrual blood loss and a 58% reduction in Pictorial Blood Assessment Chart scores from baseline to day 90. Improvement was also observed in bleeding duration, absorbent product usage, clot passage and bleeding-related urgency. Menstrual pain symptoms improved considerably, with 68.06% of participants reporting complete resolution of dysmenorrhoea at the end of treatment. Mean haemoglobin levels showed modest improvement, whilst endometrial thickness remained stable throughout the study period. No clinically significant adverse events were reported, indicating a favourable safety profile. Conclusions: Menohelp Syrup was well tolerated and was associated with clinically meaningful improvement in HMB, bleeding-related symptom burden and quality-of-life outcomes in women with HMB. These findings support the potential role of Menohelp Syrup as a safe, non-invasive therapeutic option for the management of HMB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.